News
MANE
112.71
+1.54%
1.71
This Insider Has Just Sold Shares In Veradermics
Simply Wall St · 15h ago
We Think Veradermics (NYSE:MANE) Can Afford To Drive Business Growth
Simply Wall St · 2d ago
Citi Sticks to Its Buy Rating for Veradermics, Incorporated (MANE)
TipRanks · 3d ago
Buy Rating Reaffirmed on Strong VDPHL01 Data and Catalyst-Rich Roadmap; Price Target Maintained at $164
TipRanks · 4d ago
Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate
Benzinga · 5d ago
Veradermics: Q2 Earnings Snapshot
Barchart · 5d ago
Analysts Are Bullish on Top NA Stocks: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX)
TipRanks · 5d ago
Veradermics sees cash runway into 2030
TipRanks · 5d ago
Veradermics reports Q2 net loss ($23.5M) vs. ($15.6M) last year
TipRanks · 5d ago
Press Release: Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Dow Jones · 5d ago
*Veradermics 2Q >MANE
Dow Jones · 5d ago
Weekly Report: what happened at MANE last week (0803-0807)?
Weekly Report · 6d ago
Veradermics registers to sell 16.77M shares of common stock
TipRanks · 08/07 21:15
Weekly Report: what happened at MANE last week (0727-0731)?
Weekly Report · 08/03 10:32
Weekly Report: what happened at MANE last week (0720-0724)?
Weekly Report · 07/27 10:37
Veradermics: Wait For The Post-Lockup, But Buy Before The Roll-Up
Seeking Alpha · 07/27 06:30
Weekly Report: what happened at MANE last week (0713-0717)?
Weekly Report · 07/20 10:33
Veradermics, Incorporated (MANE) Receives a Buy from LifeSci Capital
TipRanks · 07/18 21:05
Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data
NASDAQ · 07/18 05:19
Veradermics: VDPHL01 Looks Promising Enough On Paper
Seeking Alpha · 07/17 12:40
More
Webull provides a variety of real-time MANE stock news. You can receive the latest news about VERADERMICS INC through multiple platforms. This information may help you make smarter investment decisions.
About MANE
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.